Global Antibacterials Market Set to Grow to Over US$45 Billion by 2012.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c70373) has announced the addition of The Global Antibacterials Market: R&D Pipelines, Market Analysis and Competitive Landscape to their offering. The global anti-infective market is currently valued at US$66.5 billion with antibacterial antibacterial /an·ti·bac·te·ri·al/ (-bak-ter´e-al) destroying or suppressing growth or reproduction of bacteria; also, an agent that does this. an·ti·bac·te·ri·al adj. agents accounting for over 50% of sales. The antibacterial market is set to grow to over US$45.0 billion by 2012, driven by the uptake of newer antibacterial agents such as glycopeptides and carbapenems which demonstrate resistance to methicillin-resistant Staphylococcus aureus methicillin-resistant Staphylococcus aureus Methicillin-aminoglycoside resistant Staphylococcus aureus, MRSA An organism with multiple antibiotic resistances–eg, aminoglycosides, chloramphenicol, clindamycin, erythromycin, rifampin, tetracycline, (MRSA MRSA Methicillin-resistant Staphylococcus aureus. See MARSA. ) and vancomycin-resistant Enterococcus vancomycin-resistant enterococcus Infectious disease An enterococcus, primarily Enterococcus faecium, resistant to most antibiotics, including aminoglycosides and vancomycin, once a 'last-resort' agent; VRE is primarily nosocomial, in long (VRE VRE vancomycin-resistant enterococcus. VRE Vancomycin-resistent enterococcus, see there ) as well as other emerging strains. Pharmaceutical companies continue to develop a new generation of antibacterial agents such as cephalosporins Cephalosporins Definition Cephalosporins are medicines that kill bacteria or prevent their growth. Purpose Cephalosporins are used to treat infections in different parts of the body—the ears, nose, throat, lungs, sinuses, and , macrolides and quinolones to overcome the major issue of drug resistance. In addition, a number of new drug classes such as dihydrofolate reductase dihydrofolate reductase enzyme catalyzing the conversion of folate to 5,6,7,8-tetrahydrofolate, which is the key carrier of one-carbon units in purine and pyridime synthesis, the pathway for the breakdown of histidine and the synthesis of S-adenosylmethionine from S inhibitors (DHFR DHFR Dihydrofolate reductase, see there ) are under evaluation which are effective in multi drug resistant organisms. This report examines each of the antibacterial classes in turn, assessing the market potential and application in hospital and community-acquired infections. The following product classes are analyzed in this report: - aminoglycosides - carbapenems - cephalosporins - dihydrofolate reductase inhibitors - glycopeptides - ketolides - lipopeptides - macrolides - penicillins - oxazolidinones - pleuromutulins - quinolones The report assesses the overall antibacterial market, key classes and the drivers and resistors influencing their prescription. The report provides an overview of key products in each category, summarizing their clinical efficacy and marketing position. The overview of the current market is given in terms of segmentation and by leading players and their products and analyzes market trends. The report also examines promising pipeline products and their potential impact on the prescription of current and new antibacterial agents and the future of the antibacterial market. Key Features of this report: - Overview of the antibacterial market, including the main infectious agents infectious agent Pathogen, see there , therapeutic drug classes and key players. - In-depth analysis of different classes of antibacterial agents, including leading antibacterial agents and a summary of leading brands within each class. - Comprehensive facts and figures for the antibacterial market, including main players and drug class break-downs. - Future trends in the antibacterial marketplace, driven by drug resistance and patient demographics. - Outlook for the antibacterial market, including the emergence of novel therapies and the impact of generics. For more information visit http://www.researchandmarkets.com/reports/c70373 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion